Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 25Parkinson Disease 4, Autosomal Dominant Lewy Body 19Multiple Myeloma 13Neoplasms 12Leukemia, Myeloid, Acute 12Ovarian Neoplasms 10Neoplasm Metastasis 10Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 10Prostatic Neoplasms 8Colorectal Neoplasms 8Melanoma 7Lymphoma, Non-Hodgkin 7Leukemia 7Stomach Neoplasms 6Recurrence 6Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Carcinoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 5Adenocarcinoma 5Purpura, Thrombocytopenic, Idiopathic 4Myelodysplastic Syndromes 4Lymphoma, Follicular 4Liver Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4

Interventions

Mitomycin 2avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Carcinoma, Transitional Cell × Clear all
NCT05243550 2026-05-11

ENVISION

UroGen Pharma Ltd.

Phase 3 Active not recruiting
240 enrolled 20 charts 1 FDA
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02603432 2024-03-27

JAVELIN Bladder 100

Pfizer

Phase 3 Completed
700 enrolled 35 charts 1 FDA
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT02793128 2020-12-22

Olympus

UroGen Pharma Ltd.

Phase 3 Completed
71 enrolled 16 charts 1 FDA
Genitourinary

Carcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡